No more than 15 authors can be listed.Please ensure the authors are listed in the right order.If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.
Managing pulmonary tuberculosis (PTB) in elderly patients with comorbidities presents significant diagnostic and therapeutic challenges, particularly when treatment failure occurs despite appropriate therapy. This case highlights an underlying immunodeficiency in refractory PTB complicated by drug reactions and misleading autoimmune findings.
A 71-year-old woman with Hashimoto’s thyroiditis was diagnosed with smear-positive, pansensitive PTB in April 2025. Despite five months of strict adherence to intensive-phase anti-tuberculosis therapy, sputum conversion was not achieved, with persistent microbiological positivity and minimal radiological improvement. Her course was complicated by severe anti-TB drug–induced erythroderma, suspected to be secondary to isoniazid, rifampicin, or pyrazinamide, necessitating regimen modification. Escalation of rifampicin dosing further complicated management by requiring significant levothyroxine dose adjustments due to hepatic enzyme induction. Multidrug-resistant TB was excluded through repeated GeneXpert and line probe assays, while imaging and fungal investigations ruled out alternative infectious etiologies. Further evaluation revealed an initial false-positive HIV result, with undetectable HIV RNA and preserved CD4/CD8 counts. Strongly positive antinuclear antibodies were attributed to underlying autoimmune thyroid disease. Immunological testing showed elevated IgG1, reduced IgG2 subclass levels, and low IgM levels, with no increase in double-negative T cells, leading to a diagnosis of common variable immunodeficiency (CVID). She was subsequently treated with levofloxacin, linezolid, clofazimine, and ethambutol, and achieved sputum conversion following two cycles of intravenous immunoglobulin (IVIG).
CVID impairs both humoral and cellular immune responses against Mycobacterium tuberculosis. In this case, apparent treatment failure reflected host immune dysfunction rather than drug resistance. The coexistence of autoimmunity and severe drug reactions highlights the immune dysregulation characteristic of CVID.
Conclusion: This case underscores the importance of evaluating for immunodeficiency in refractory PTB. Although rare in the elderly, late-onset CVID can mimic chronic infection and autoimmunity. Early recognition is crucial, as immunoglobulin replacement is key to achieving effective disease control.